Vanguard Group
BBOT

Vanguard Group’s BridgeBio Oncology BBOT Stock Holding History

Vanguard Group’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$9.9M Buy
791,095
+143,496
+22% +$1.74M ﹤0.01% 2972
2025
Q3 		$7.5M Buy
+647,599
New +$6.75M ﹤0.01% 3125

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Vanguard Group's BBOT Position: Q4 2025 in Review

Vanguard Group increased its BridgeBio Oncology (BBOT) stake by 22% in Q4 2025, buying an estimated $1.74M and bringing the position to 791,095 shares worth $9.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2972.

Vanguard Group first reported a position in BBOT in Q3 2025 and has held it in 2 quarters since. 53 funds tracked by Wall St. Rank hold BBOT as of Q4 2025.

  • Vanguard Group held 791,095 shares of BridgeBio Oncology worth $9.9M as of Q4 2025.
  • Vanguard Group bought 143,496 BridgeBio Oncology shares in Q4 2025, an estimated $1.74M.
  • BridgeBio Oncology made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2972 holding.
  • Vanguard Group first reported a position in BridgeBio Oncology in Q3 2025 and has held it in 2 quarters since.
  • 53 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.